Therapeutic potential of apixaban at different stages of management of patients with pulmonary thromboembolism
| Autor: | O. V. Averkov, V. I. Vechorko, O. A. Shapsigova |
|---|---|
| Jazyk: | ruština |
| Rok vydání: | 2019 |
| Předmět: | |
| Zdroj: | Медицинский совет, Vol 0, Iss 21, Pp 8-15 (2019) |
| Druh dokumentu: | article |
| ISSN: | 2079-701X 2658-5790 |
| DOI: | 10.21518/2079-701X-2018-21-8-15 |
| Popis: | The article discusses the issues of anticoagulant therapy in pulmonary thromboembolism. It clearly highlights the main advantages and the preferred use of direct selective oral anticoagulants represented by the thrombin inhibitor dabigatran and the factor Xa inhibitor group including apixaban, edoxaban and rivaroxaban. This article provides a thorough introduction of apixaban with an evidence base allowing to consider it a priority anticoagulant, which may be reasonably administered to the majority of patients with pulmonary thromboembolism from the first hours of the disease to many years of secondary prevention. |
| Databáze: | Directory of Open Access Journals |
| Externí odkaz: |
|